US private equity firm Carlyle Group is set to exit Indegene Ltd. by selling shares for at least Rs 1,420 crore via open market transactions on Wednesday.
Carlyle affiliate CA Dawn Investments has offered to sell over 2.4 crore shares at a floor price of Rs 580 per share, according to the term sheet accessed by NDTV Profit. The floor price is at a 6.41% discount to Tuesday's close on the NSE.
The offer represents the entire 10.2% equity held by Carlyle in the company.
IIFL Capital Services Ltd. and Kotak Securities Ltd. are the bookrunners for the block deal.
"No guidance will be given on pricing until the shares are crossed on the Indian Stock Exchanges on 04 June 2025. Investors should indicate the demand sensitivities across the price range," the term sheet said.
Bengaluru-based Indegene provides consulting in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.
Shares settled 2.31% higher at Rs 618.9 apiece on the BSE, compared to a 0.8% decline in the benchmark Sensex. The stock has risen 16% since its listing in May last year.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
